AMGN vs VRTX
AMGN and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $236.87B | $138.80B |
| P/E (TTM) | 27.2 | 31.9 |
| P/B | 20.27 | 6.86 |
| P/S | 6.4x | 11.6x |
| Dividend yield | 2.16% | — |
| Revenue | $38.09B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 10.0% | 8.9% |
| Net income | $8.74B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 88.5% | 838.1% |
| EPS, diluted | $16.10(TTM) | $17.17(TTM) |
| EBIT margin | 24.7% | 34.8% |
| ROE | 66.0% | 19.5% |
| ROIC | 15.1% | 25.0% |
| 1y total return | +55.2% | +37.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: AMGN frente a VRTX
| Métrica | AMGN | VRTX |
|---|---|---|
| Valor final | $37.8K | $64.9K |
| Retorno total | +277.6% | +549.3% |
| CAGR | +13.7% | +19.8% |
| Volatilidad | 24.8% | 32.8% |
| Sharpe | 0.48 | 0.60 |
| Sortino | 0.72 | 0.88 |
| Caída máxima | -24.9% | -41.6% |
Basado en 2600 días de negociación comunes, 2016-04-29 → 2026-09-01 · tasa libre de riesgo 3.92% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)